Novel Multiple Myeloma Therapy Enters First-in-Human Trial
Innovent Biologics has initiated a first-in-human Phase I/II clinical trial for IBI3003, a novel investigational therapeutic targeting patients with relapsed or refractory multiple myeloma (MM). The trial NCT07336472 will evaluate the safety, tolerability, and preliminary efficacy of IBI3003 in patients who have failed at least three prior lines of treatment, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38-based therapies.
The trial will employ a dose-escalation design, with an anticipated enrollment of approximately 60 patients across multiple clinical sites. Researchers will assess multiple endpoints, including adverse events, objective response rate, minimal residual disease negativity, and pharmacokinetic parameters. Patients will be closely monitored to establish the compound's safety profile and initial therapeutic potential in this challenging patient population.
Research Context
Multiple myeloma represents a significant clinical challenge, with limited treatment options for patients who have progressed through standard therapeutic approaches. Current management strategies typically involve combinations of proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. However, the development of drug resistance and limited efficacy in heavily pretreated patients underscore the critical need for novel therapeutic interventions.